BioCentury

7:00 AM GMT, Jun 3, 2002
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Breathing some half-life into Cialis

A recent hiccup at the FDA took Cialis from Lilly Icos LLC out of a dead heat with Bayer AG's vardenafil to become the second phosphodiesterase-5 inhibitor to reach the U.S. market for erectile dysfunction. But data presented at the American Urological Association (AUA) meeting in Orlando may give Lilly Icos the marketing hook it needs to grab market share once it gets final approval.

Both Cialis tadalafil and vardenafil are oral selective PDE-5 inhibitors, like Viagra sildenafil from Pfizer Inc. (PFE, New York, N.Y.). According to

Read the full 875 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.